The most important molecular biomarkers for GBM include the methylation status of O-6-methylguanine-FNA methyltransferase (MGMT) promoter, and the mutational status of the isocitrate dehydrogenase 1 and 2 (IDH1, IDH2). This evidence concerns the gene IDH1 and glioblastoma.